Human oxaloacetate decarboxylase inhibitors for metabolic and neurological diseases


The invention identifies human oxaloacetate decarboxylase (hODx) as a new pharmacological target for the treatment of common metabolic and neurological diseases and provides pilot compounds that inhibit hODx in the micromolar range. The technology was invented by researchers at Innsbruck University.

Category

Lifescience

Projektnumber

P1404018

Patent Status

EP application October 2014

Description

The invention identifies human oxaloacetate decarboxylase (hODx) as a new pharmacological target for the treatment of common metabolic and neurological diseases and provides pilot compounds that inhibit hODx in the micromolar range. The technology was invented by researchers at Innsbruck University.

Application

  • Treat obesity and hypercholesterinemia by stimulating fatty acid oxidation
  • Combat diseases associated with genetic and lifestyle-driven PC deficiency
  • New option to treat neurological disorders by causative therapy
  • Extension of technology possible to other diseases with PC involvement (e.g. diabetes mellitus)

Benefits

  • New mode of action for metabolic and neurological diseases

Cooperation Options

  • License agreement
  • development partnership

Contact

Dr. Angela Siegling
Schutzrechtsmanagement
+ 43 1 501 75 - 552